Quick Summary
49,500 monthly US searches at low keyword difficulty — highest search volume in the GH secretagogue category after Sermorelin; natural cross-sell with CJC-1295 No DAC via the 2X Blend.
Ipamorelin (CAS: 170851-70-4) is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, MW: 711.85 Da) developed by Novo Nordisk A/S and first described by Raun et al. in 1998 as the first selective growth hormone secretagogue — the first GHRP-receptor agonist to release GH without significant ACTH, cortisol, or prolactin elevation.
A 2014 Phase 2 randomized controlled trial (n=87, Int J Colorectal Dis) evaluated ipamorelin for postoperative ileus management in bowel resection research subjects — the most rigorous published human study to date (Beck et al., PMID: 25331030).
Primary mechanism: selective GHS-R1a (ghrelin receptor) agonism producing pulsatile GH release; published pharmacokinetic data documents GH peak at approximately 40 minutes post-administration in animal models (Gobburu et al., PMID: 10496658).
Preclinical data demonstrates stimulation of longitudinal bone growth (Johansen et al., PMID: 10373343) and counteraction of glucocorticoid-induced bone formation reduction (Andersen et al., PMID: 11735244).
Research-grade ipamorelin is available in a 10mg configuration and as part of the 2X Blend with CJC-1295 No DAC for combination GH-axis research protocols (Research Use Only).
One response to “Ipamorelin: Complete Research Guide — Selective GH Secretagogue Mechanism, Human Data & White-Label Pricing (2026)”
Hi, this is a comment.
To get started with moderating, editing, and deleting comments, please visit the Comments screen in the dashboard.
Commenter avatars come from Gravatar.